logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
15-Nov-2022 To 15-Dec-2022
Gossamer Bio Inc.
Topline data from phase II trial of Seralutinib (TORREY )
Pulmonary Arterial Hypertension
Q4 2022
Gossamer Bio Inc.
36-week topline data from phase II clinical trial of GB004 (SHIFT-UC )
Active ulcerative colitis
Q4 2022
Context Therapeutics Inc.
Preliminary data from phase 2 trial of ONA-XR
2L/3L metastatic breast cancer
Q4 2022
FEMASYS INC
Interim data from pivotal trial of FemaSeed (LOCAL)
Artificial insemination
Q4 2022
Mirum Pharmaceuticals Inc.
Topline data from phase III trial of Livmarli (MARCH-PFIC)
Progressive familial intrahepatic cholestasis Type 2
Q4 2022
SELLAS Life Sciences Group, Inc.
Final data from phase I/II trial of Galinpepimut-S (GPS) in combination with Keytruda for up to 17 patients
Second or third line Wilms Tumor-1 (WT1)(+) relapsed or refractory metastatic ovarian cancer
Q4 2022
Ascendis Pharma A/S
Topline data from phase I/II clinical trial of TransCon IL-2 ß/? (IL-ßelie?e)
advanced cancer
Q4 2022
Mirum Pharmaceuticals Inc.
Top-line data readout phase III trial of Maralixibat(MARCH-PFIC)
Progressive Familial Intrahepatic Cholestasis in children
Q4 2022
X4 Pharmaceuticals, Inc.
Top-line results from Phase 3 trial of mavorixafor
WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome
Q4 2022
Caladrius Biosciences, Inc.
Top line data from phase IIb trial of CLBS16 in the U.S.(FREEDOM)
Coronary microvascular dysfunction
Q4 2022
Addex Therapeutics Ltd
Data from phase IIb/III study of Dipraglurant
Dyskinesia associated with Parkinson's disease
Q4 2022
Pharvaris N.V.
Topline data from phase II clinical trial of PHVS416 (CHAPTER-1)
Prophylactic treatment of HAE attacks
Q4 2022
Candel Therapeutics, Inc.
Data from phase 1b clinical trial of CAN-2409 in combination with Opdivo
1st line treatment in patients with newly diagnosed high-grade glioma
Q4 2022
Candel Therapeutics, Inc.
Data from phase I clinical trial of CAN-3110
Recurrent high-grade glioma
Q4 2022
Affimed N.V.
Topline data from phase II study of AFM13 monotherapy (REDIRECT)
Relapsed or refractory CD30-positive peripheral T-cell lymphoma
Q4 2022
Aligos Therapeutics, Inc
Top line results from 12-week cohort of phase I trial of ALG-000184
Healthy volunteers and chronic hepatitis B patients
Q4 2022
Vera Therapeutics, Inc.
Primary endpoint data from phase IIb trial of Atacicept(ORIGIN)
IgA Nephropathy
Oct 2022
Tricida, Inc.
Topline results from phase IIIb study of Veverimer (VALOR-CKD)
Delaying chronic kidney disease progression in subjects with metabolic acidosis
Q4 2022
Immunic, Inc
Initial results from phase 1 clinical trial of IMU-935
Moderate-to-severe psoriasis.
Q4 2022
Rain Therapeutics Inc.
Interim data from phase II basket trial of Milademetan (MANTRA-2)
MDM2-amplified advanced solid tumors
Q4 2022
Dynavax Technologies Corp
Interim adult data from phase I clinical trial of tetanus, diphtheria, and acellular pertussis (Tdap) booster vaccine candidate adjuvanted with CpG 1018
hepatitis B virus vaccine in adults
Q4 2022
Dynavax Technologies Corp
Topline data from phase 1 clinical trial comparing shingles vaccine candidate, adjuvanted with CpG 1018, with Shingrix
Vaccine
Q4 2022
Design Therapeutics, Inc.
Topline data from phase I trial of DT-216
Friedreich ataxia in adults
Q4 2022
Synthetic Biologics Inc.
Data read out from first cohort of phase Ib/IIa trial of SYN-004
Allogeneic hematopoietic cell transplantation (allo-HCT) recipients in adults
Q4 2022
Synaptogenix, Inc.
Topline data from phase IIb clinical trial of Bryostatin-1
Advanced and moderately severe Alzheimer's disease